Literature DB >> 1700842

Substance P-like immunoreactivity at the frog neuromuscular junction.

M Matteoli1, C Haimann, P De Camilli.   

Abstract

It has been recently shown that frog motoneurons and their nerve terminals contain calcitonin gene-related peptide-like immunoreactivity in large dense-core vesicles (Matteoli et al., Proc. natn. Acad. Sci. U.S.A. 85, 7366-7370, 1988). We report here by an immunofluorescence approach that the same neurons and nerve terminals also contain substance P-like immunoreactivity. The demonstration of substance P-like immunoreactivity in the frog motor nerve endings supports previous data suggesting a physiological role for this peptide in the modulation of cholinergic transmission.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1700842     DOI: 10.1016/0306-4522(90)90213-n

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  5 in total

1.  In vivo long-term synaptic plasticity of glial cells.

Authors:  Eve-Lyne Bélair; Joanne Vallée; Richard Robitaille
Journal:  J Physiol       Date:  2010-02-08       Impact factor: 5.182

2.  Interactions between tachykinins and diverse, human nicotinic acetylcholine receptor subtypes.

Authors:  R J Lukas; C M Eisenhour
Journal:  Neurochem Res       Date:  1996-10       Impact factor: 3.996

3.  Muscarinic control of cytoskeleton in perisynaptic glia.

Authors:  J Georgiou; R Robitaille; M P Charlton
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

4.  Endogenous peptidergic modulation of perisynaptic Schwann cells at the frog neuromuscular junction.

Authors:  M J Bourque; R Robitaille
Journal:  J Physiol       Date:  1998-10-01       Impact factor: 5.182

5.  Immunohistological and electrophysiological evidence that N-acetylaspartylglutamate is a co-transmitter at the vertebrate neuromuscular junction.

Authors:  Kathryn K Walder; Steve B Ryan; Tomasz Bzdega; Rafal T Olszewski; Joseph H Neale; Clark A Lindgren
Journal:  Eur J Neurosci       Date:  2012-11-08       Impact factor: 3.386

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.